Sugi Predict

Sugi Predict / Compounds / SCHEMBL106341

SCHEMBL106341

SCHEMBL106341

O=C(Cl)c1ccc(F)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.54
▸ CES2 O00748 2/20 0.48
▸ CES1 P23141 2/20 0.48
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ PYGL P06737 4/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ P2RX7 Q99572 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ ALOX15 P16050 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSD11B1 P28845 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8703978 0.88 CES2 (0.48) HPGDCES2CES1NPC1RAB9A
SCHEMBL23755037 0.84 CES2 (0.61) HPGDCES2CES1NPC1RAB9A
SCHEMBL29873483 0.84 CES2 (0.61) HPGDCES2CES1NPC1RAB9A
SCHEMBL2861947 0.84 HPGD (0.61) HPGDCES2CES1NPC1RAB9A
SCHEMBL195310 0.83 TSHR (0.63) HPGDCES2CES1NPC1RAB9A
SCHEMBL477556 0.83 CES2 (0.48) HPGDCES2CES1ALDH1A1ALOX15
SCHEMBL9834572 0.82 CES2 (0.52) HPGDCES2CES1NPC1RAB9A
SCHEMBL30231714 0.81 HPGD (0.53) HPGDCES2CES1NPC1RAB9A
SCHEMBL473969 0.81 HPGD (0.53) HPGDCES2CES1NPC1RAB9A
SCHEMBL2839520 0.81 KMT2A (0.53) HPGDCES2CES1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 502 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115703648-A Modified zinc oxide, preparation method thereof and light-emitting diode TCL科技集团股份有限公司 2023-02-17 — — CN claimed
CN-105503562-B Bis- [the fluoro- 2- of 5- (4 '-methoxybenzoyl base)] biphenyl and its synthetic method 南京理工大学 2019-01-04 — — CN claimed
CN-122036735-A Pyrazolo [3,4-d ] pyrimidine-hydroxamic acid derivatives, synthetic method and application 云南大学 2026-05-15 — — CN disclosed
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 — — EP disclosed
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-14 — — US disclosed
US-12338243-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-06-24 — — US disclosed
US-20250171457-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-05-29 — — US disclosed
CN-120025312-A Benzazepine derivatives 大塚制药株式会社 2025-05-23 — — CN disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 — — US disclosed
US-20250084093-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-03-13 — — US disclosed
US-12247027-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-03-11 — — US disclosed
US-4704483-A FLUORINATION WITH POTASSIUM FLUORIDE OCCIDENTAL CHEMICAL CORPORATION (US) 1987-11-03 — — US disclosed
US-4582948-A VAPOR PHASE CHLORO-DENITRATION REACTION OCCIDENTAL CHEMICAL CORPORATION (US) 1986-04-15 — — US disclosed
EP-0159388-A2 Preparation of nuclear chlorinated compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1985-10-30 — — EP disclosed
US-4470930-A Preparation of nuclear chlorinated aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1984-09-11 — — US disclosed
US-4064132-A ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1977-12-20 — — US disclosed
US-4060528-A ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-11-29 — — US disclosed
US-4035376-A ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 — — US disclosed
US-3985889-A 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS AMERICAN HOECHST CORPORATION (US) 1976-10-12 — — US disclosed
US-3962259-A TRANQUILIZERS, ANALGETIC AGENTS AMERICAN HOECHST CORPORATION (US) 1976-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247027-B2 P2X7 modulators P2RX2, P2RX7, P2RY2 HPGD 807/4885CES2 2281/4885CES1 2656/4885
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 HPGD 3540/4885CES2 2017/4885CES1 2193/4885
US-12338243-B2 P2X7 modulators P2RX7, P2RX4, P2RX1 HPGD 725/4885CES2 2229/4885CES1 1537/4885
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect KEAP1, NFE2L2, BACH1 HPGD 1510/4885CES2 2878/4885CES1 1817/4885
US-20250171457-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT KEAP1, NFE2L2, BACH1 HPGD 1510/4885CES2 2878/4885CES1 1817/4885
US-20250084093-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT KEAP1, NFE2L2, BACH1 HPGD 1483/4885CES2 2899/4885CES1 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.